Omini

Omini is a France-based health care company developing a new generation of portable, immediate blood tests performed at the patient's side. Its patented biosensor technology is described as combining the accuracy of traditional laboratory methods with the portability and connectivity of connected devices, with the stated aim of bringing lab testing closer to the patient.

Company directory listings position the product both for professional point-of-care use and for self-testing performed by patients at home, with providers kept informed of results. The company frames its objectives around decentralised care, patient empowerment in managing their own health, telemedicine and personalised medicine. It is categorised as MedTech / health care, with technology areas listed as hardware, life science and medical equipment.

Business model

Directory data lists Omini's business model as B2B and B2B2C, indicating sales to or through organisations such as health care providers and industry partners rather than purely direct-to-consumer distribution. Omini states it is seeking distribution partnerships and co-development arrangements.

Traction

Public sources report a small team of three people and total disclosed funding in the range of €1 million to €2.5 million (EU-Startups), while a French startup directory records a €530,000 seed raise. Partner affiliations listed include Medicen Paris Region and Station F.

Latest developments

No dated developments after 2020 are reported in the available sources; directory listings continue to describe the company as operating with a seed-stage funding profile.